How to Get Evenity (Romosozumab) in Minnesota

Who Can Prescribe Evenity in Minnesota

Any licensed MD, DO, NP, or PA in Minnesota can write a prescription for romosozumab, though most prescriptions originate from endocrinologists, rheumatologists, or orthopedic specialists. Minnesota Statute 151.37 grants prescriptive authority to nurse practitioners and physician assistants with active collaborative agreements or independent practice status, meaning you do not necessarily need to see a physician directly.

Referral patterns matter here. Primary care providers often identify osteoporosis through routine DEXA screening but refer patients to specialists for anabolic bone agents like romosozumab. The Endocrine Society's 2020 clinical practice guideline recommends anabolic-first therapy for patients at very high fracture risk, defined as a recent osteoporotic fracture, a T-score of −3.0 or below, or a high FRAX probability. If your PCP hesitates to prescribe, request a referral to an endocrinologist or a bone health clinic at a system like Mayo Clinic, Hennepin Healthcare, or M Health Fairview.

Telehealth prescribing is fully legal in Minnesota for romosozumab. The Minnesota Board of Medical Practice permits establishing a patient-provider relationship via synchronous audio-video visit. A telehealth clinician licensed in Minnesota can order your baseline labs, submit the prior authorization, and send the prescription to a specialty pharmacy. The injection itself still requires in-person administration (two subcutaneous injections per visit, each in a prefilled syringe), so you will need a local infusion center, clinic, or home health nurse to administer the monthly doses.

Required Labs Before Starting Romosozumab

Your prescriber will order baseline labs before the first injection, and certain values can delay or disqualify treatment. Getting these drawn early saves time.

The FDA-approved prescribing information for Evenity mandates correction of hypocalcemia before initiating therapy. At minimum, expect orders for serum calcium (corrected for albumin), 25-hydroxyvitamin D, a basic metabolic panel assessing renal function (eGFR and creatinine), and a complete blood count. Many clinicians also request a baseline P1NP (procollagen type I N-propeptide) and CTX (C-terminal telopeptide) to establish bone turnover markers before treatment and track response at 3, 6, and 12 months.

Vitamin D levels below 30 ng/mL should be repleted before the first dose. A common repletion protocol is ergocalciferol 50,000 IU weekly for 8 weeks, then maintenance dosing of 1,000 to 2,000 IU daily. Calcium intake should reach at least 1,000 mg daily through diet or supplementation. The ARCH trial (N=4,093) required adequate calcium and vitamin D status at enrollment, and real-world prescribers follow the same standard.

If your eGFR falls below 30 mL/min/1.73m², your clinician will weigh the risk-benefit ratio carefully. Romosozumab is not contraindicated in chronic kidney disease, but hypocalcemia risk rises with declining renal function. More frequent calcium monitoring (every 2 weeks for the first 2 months) is standard practice for patients with stage 4 or 5 CKD.

Prior Authorization Steps in Minnesota

Nearly every commercial insurer, Medicare Part B plan, and Minnesota Medicaid (Medical Assistance) requires prior authorization for Evenity. The drug's wholesale acquisition cost exceeds $1,800 per monthly dose, which places it in specialty tiers across all Minnesota payers. Do not assume your prescription will be filled without PA approval.

Documentation your prescriber will need to submit includes: a DEXA scan report showing a T-score of −2.5 or lower at the lumbar spine, femoral neck, or total hip; a clinical rationale describing high fracture risk (prior fragility fracture, FRAX 10-year major osteoporotic fracture probability exceeding 20%, or FRAX hip fracture probability exceeding 3%); evidence that the patient has tried or has a contraindication to bisphosphonates (alendronate, risedronate, or zoledronic acid); and recent lab work confirming corrected calcium within normal limits.

Minnesota Medicaid specifically covers romosozumab for severe osteoporosis with PA. The Minnesota Department of Human Services pharmacy program uses step-therapy criteria that typically require documented failure of, intolerance to, or contraindication to at least one oral bisphosphonate. If you have a history of esophageal stricture, achalasia, or inability to remain upright for 30 minutes after dosing, these qualify as contraindications and should be documented.

PA turnaround in Minnesota usually takes 5 to 10 business days. If denied, your prescriber can file a peer-to-peer review or a formal appeal. Specialty pharmacies like Optum Specialty, Accredo, and CVS Specialty often have dedicated prior authorization teams that handle the submission on behalf of your prescribing clinic.

The HealthRX Minnesota Evenity Access Checklist

This step-by-step checklist distills the access pathway into a concrete sequence, organized by week, so patients and referring providers can track progress from initial evaluation through first injection.

Week 1 to 2: Evaluation. Schedule an appointment (in-person or telehealth) with a prescriber licensed in Minnesota. Bring your most recent DEXA scan. If you do not have one within the past 24 months, request a new scan. Have baseline labs drawn: serum calcium, 25-hydroxyvitamin D, BMP, CBC, P1NP, and CTX.

Week 2 to 3: Lab Review and Repletion. Your clinician reviews results. If vitamin D is below 30 ng/mL, begin repletion immediately. If calcium is low, start supplementation and recheck in 2 weeks. Address any cardiovascular contraindications per the black box warning: romosozumab is contraindicated in patients who have had a myocardial infarction or stroke within the preceding 12 months, as noted in the FDA label.

Week 3 to 4: Prior Authorization Submission. Your prescriber or the specialty pharmacy submits PA with DEXA report, lab results, fracture history, FRAX score, and bisphosphonate trial/failure documentation. Expect a decision within 5 to 10 business days.

Week 4 to 6: Pharmacy Coordination. Once PA is approved, the specialty pharmacy ships Evenity (two 105 mg/1.17 mL prefilled syringes per dose) to your administering clinic or, in some cases, directly to your home with a home health nurse arrangement. Cold chain shipping is required; the drug must be refrigerated at 2°C to 8°C.

Week 6 to 7: First Injection. A trained healthcare professional administers two subcutaneous injections (one in each thigh, or one in the abdomen and one in the thigh) at your clinic or infusion center. The full 210 mg dose is split across two syringes because each prefilled syringe contains 105 mg.

Clinical Evidence Supporting Romosozumab

Romosozumab received FDA approval in April 2019 based on two key trials. The drug works by inhibiting sclerostin, a glycoprotein produced by osteocytes that normally suppresses bone formation. Blocking sclerostin simultaneously increases bone formation and decreases bone resorption, a dual mechanism unique among osteoporosis therapies.

The ARCH trial, published in the New England Journal of Medicine in 2017, enrolled 4,093 postmenopausal women with osteoporosis and a prior fragility fracture. Patients received either romosozumab 210 mg monthly for 12 months followed by alendronate, or alendronate alone for the full study period. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% compared to alendronate alone (6.2% vs. 11.9%, P<0.001). Non-vertebral fracture risk dropped by 19% at 24 months.

The FRAME trial (N=7,180), published in the same journal, compared romosozumab to placebo for 12 months, both followed by denosumab. At 12 months, romosozumab reduced new vertebral fractures by 73% versus placebo (0.5% vs. 1.8%, P<0.001). Lumbar spine BMD increased by 13.3% from baseline in the romosozumab group at 12 months, versus 0.0% with placebo.

These gains are not permanent. Once the 12-month romosozumab course ends, patients must transition to an anti-resorptive agent (typically denosumab 60 mg every 6 months, or a bisphosphonate) to maintain the bone density gains. The Endocrine Society guideline explicitly recommends sequential therapy after romosozumab, calling the anabolic-to-antiresorptive sequence the preferred approach for very high-risk patients.

One clinical consideration that is sometimes under-discussed: the ARCH trial also showed a higher incidence of serious cardiovascular events in the romosozumab arm during the first 12 months (2.5% vs. 1.9% with alendronate). This led the FDA to include a black box warning. Prescribers in Minnesota, as elsewhere, must evaluate cardiovascular risk before initiating therapy. Dr. Clifford Rosen, a senior scientist at Maine Medical Center Research Institute and co-author of a NEJM editorial on romosozumab, stated: "The cardiovascular signal in ARCH requires clinicians to weigh fracture reduction benefits against potential cardiac risk on a case-by-case basis."

Specialty Pharmacy and 503A Access in Minnesota

Evenity is a specialty drug distributed through a limited pharmacy network. Most patients in Minnesota fill their prescriptions through one of three major specialty pharmacies: Optum Specialty Pharmacy (headquartered in the Twin Cities metro), Accredo (Express Scripts), or CVS Specialty. These pharmacies handle cold-chain shipping, patient onboarding, and refill coordination for the full 12-month course.

Licensed 503A compounding pharmacies in Minnesota can also participate in the distribution chain, though romosozumab itself is a biologic and not a compounded product. The 503A pathway is more relevant for adjunct medications (such as compounded vitamin D or calcium formulations) that may accompany the treatment plan. For the biologic itself, you will receive FDA-approved Evenity prefilled syringes manufactured by Amgen.

Patients in rural Minnesota (outside the Minneapolis-Saint Paul metro, Rochester, and Duluth corridors) can receive Evenity shipped directly to a local clinic or hospital pharmacy. Cold-chain logistics are well established; the specialty pharmacy ships in insulated packaging with temperature monitors. Typical delivery takes 2 to 5 business days after PA approval and pharmacy processing. Some patients in border communities (Moorhead, Grand Marais, International Falls) may find it faster to coordinate with a North Dakota or Wisconsin specialty pharmacy, but the prescription must originate from a Minnesota-licensed prescriber if the patient encounter occurs in Minnesota.

Home administration is technically possible but uncommon. The prescribing information states that Evenity should be administered by a healthcare professional. Some home health nursing agencies in Minnesota (such as those affiliated with Mayo Clinic Home Services or Fairview Home Care) can administer the monthly injections in the patient's home, which is particularly valuable for patients with mobility limitations.

Cost, Insurance, and Financial Assistance in Minnesota

The average wholesale acquisition cost for one month of Evenity (two prefilled syringes) is approximately $1,825 per dose, totaling roughly $21,900 for the full 12-month course. Out-of-pocket cost varies dramatically depending on insurance.

Medicare Part B typically covers Evenity as a physician-administered injectable under the medical benefit (not the pharmacy benefit). Patients on Original Medicare pay 20% coinsurance after meeting their Part B deductible ($257 in 2025), which means a monthly copay of roughly $365 per injection without supplemental coverage. A Medigap plan (Plans C, F, or G) can reduce this to zero out-of-pocket.

Commercial insurers in Minnesota (Blue Cross Blue Shield of Minnesota, Medica, HealthPartners, PreferredOne, UCare) generally place Evenity on specialty tiers with copays ranging from $50 to $250 per injection after PA approval. Some plans use coinsurance (20% to 30%) rather than flat copays, which can push monthly costs above $400.

Amgen offers the Evenity Access Program for eligible patients, providing copay assistance cards that reduce out-of-pocket costs to as low as $5 per injection for commercially insured patients. Uninsured patients or those on government insurance (Medicare, Medicaid) do not qualify for the copay card but may qualify for Amgen's patient assistance program (Amgen Safety Net Foundation), which provides Evenity at no cost to patients meeting income criteria (generally household income below 400% of the federal poverty level).

Minnesota's Medical Assistance (Medicaid) program covers Evenity with prior authorization. Copays under Medical Assistance are minimal, typically $1 to $3 per prescription. The PA criteria mirror those described above: documented osteoporosis with high fracture risk and prior bisphosphonate trial or contraindication.

What to Expect During the 12-Month Treatment Course

Each monthly visit takes approximately 15 to 30 minutes. A healthcare professional prepares two prefilled syringes (105 mg each), injects them subcutaneously in different anatomic sites (abdomen, thigh, or upper arm), and monitors you briefly for injection-site reactions. The most common adverse effects reported in the ARCH and FRAME trials were injection-site reactions (5.2% of patients), arthralgia (12.4%), and headache (4.0%) per the FDA label.

Your prescriber will likely order follow-up labs at 3, 6, and 12 months: serum calcium (to monitor for hypocalcemia), P1NP (which peaks at month 1 and declines thereafter), and CTX (which drops during treatment, reflecting reduced resorption). A follow-up DEXA scan is standard at 12 months to document BMD response before transitioning to an anti-resorptive agent.

Missed doses should be administered as soon as possible, with subsequent doses rescheduled from the date of the last injection. The treatment course should not extend beyond 12 monthly doses. Re-treatment with romosozumab has not been studied in published trials, so current practice limits use to a single 12-dose course per lifetime.

After completing 12 months of romosozumab, the transition to antiresorptive therapy is not optional. Bone density gains erode rapidly without sequential treatment. The Endocrine Society recommends either denosumab 60 mg subcutaneously every 6 months or zoledronic acid 5 mg IV annually as follow-on agents. Your prescriber should have this transition plan documented before you receive your first romosozumab injection.